Recycled Blood Superior to Banked Blood for Surgery
|
By LabMedica International staff writers Posted on 25 May 2014 |
Patients whose own red blood cells (RBCs) are recycled during cardiopulmonary bypass (CPB) surgery fare better than those who get transfusions from a blood bank, according to a new study.
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) conducted a prospective cohort study involving 32 patients undergoing cardiac surgery with CPB. The patients were divided into three groups by transfusion status: autologous salvaged RBCs alone (12 patients), autologous salvaged RBCs + minimal (less than five units) stored allogeneic RBCs (10 patients), and autologous salvaged RBCs + moderate (more than five units) stored allogeneic RBCs (10 patients). Ektacytometry was used to measure RBC deformability and aggregation before, during, and for three days after surgery.
The results showed that in patients who received only their own RBCs, elongation index did not change significantly from the preoperative baseline. The more blood a patient got from the blood bank, the more their RBCs deformed; deformability was dose-dependent, recovering toward baseline over time. Three days after surgery, however, the RBCs in the group that got the largest number of transfused units still had not recovered their full function. Changes in aggregation were unrelated to transfusion. The study was published in the June 2014 issue of Anesthesia & Analgesia.
“We now have more evidence that fresh blood cells are of a higher quality than what comes from a blood bank,” said lead author Steven Frank, MD, an associate professor of anesthesiology and critical care medicine. “If banked blood, which is stored for up to six weeks, is now shown to be of a lower quality, it makes more sense to use recycled blood that has only been outside the body for one or two hours. It's always been the case that patients feel better about getting their own blood, and recycling is also more cost effective.”
Blood recycling is achieved via a cell saver machine, which collects blood lost during surgery, rinses away unneeded fat and tissue, and then centrifuges and separates the RBCs, which are returned to the patient. Patients who lose blood may also need platelets and plasma, which they receive regardless of whether they receive their own blood or blood from a bank. Recycling first became popular during the early years of the HIV/AIDS crisis, so that patients could avoid the risk of getting the virus in transfused blood. The practice also reduces the risk of contracting hepatitis B or C infections, or of bad transfusion-related reactions.
Related Links:
Johns Hopkins Medicine
Latest Hematology News
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Channels
Clinical Chemistry
view channel
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read moreMolecular Diagnostics
view channel
Point-of-Care Molecular Technology Promises Transformative Shift in Oncology
Delays in obtaining molecular test results can hinder timely oncology decisions and widen disparities for patients far from centralized laboratories. Prolonged waits may also heighten anxiety and increase... Read more
New Test Delivers Four Prenatal Genetic Screens from One Blood Sample
Prenatal genetic screening often requires multiple tests, blood draws, and follow-up appointments, delaying access to clinically relevant information. Early, consolidated insights may help clinicians coordinate... Read more
Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
Vesicular and pustular skin lesions can stem from multiple viral pathogens, complicating timely diagnosis and management. Sequential single-pathogen testing can miss infections when the causative agent... Read more
Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
Radium-223 dichloride is a bone-targeted radiopharmaceutical therapy that improves overall survival and quality of life for many patients with metastatic castration-resistant prostate cancer (mCRPC), but... Read moreHematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read moreImmunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more








